What is the official website of Thomas Processing ?

The official website of Thomas Processing is https://thomasprocessing.com/.

What is Thomas Processing's cybersecurity risk score?

Thomas Processing has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Thomas Processing experienced?

According to Rankiteo, Thomas Processing currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Thomas Processing been affected by any supply chain cyber incidents ?

According to Rankiteo, Thomas Processing has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Thomas Processing have SOC 2 Type 1 certification ?

According to Rankiteo, Thomas Processing is not certified under SOC 2 Type 1.

Does Thomas Processing have SOC 2 Type 2 certification ?

According to Rankiteo, Thomas Processing does not hold a SOC 2 Type 2 certification.

Does Thomas Processing comply with GDPR ?

According to Rankiteo, Thomas Processing is not listed as GDPR compliant.

Does Thomas Processing have PCI DSS certification ?

According to Rankiteo, Thomas Processing does not currently maintain PCI DSS compliance.

Does Thomas Processing comply with HIPAA ?

According to Rankiteo, Thomas Processing is not compliant with HIPAA regulations.

Does Thomas Processing have ISO 27001 certification ?

According to Rankiteo,Thomas Processing is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Thomas Processing operate in ?

Thomas Processing operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Thomas Processing have ?

Thomas Processing employs approximately 0 people worldwide.

Does Thomas Processing own any subsidiaries ?

Thomas Processing presently has no subsidiaries across any sectors.

How many LinkedIn followers does Thomas Processing have ?

Thomas Processing's official LinkedIn profile has approximately 3,222 followers.

What is the NAICS classification code for Thomas Processing ?

Thomas Processing is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Thomas Processing have a Crunchbase profile ?

No, Thomas Processing does not have a profile on Crunchbase.

Does Thomas Processing have a LinkedIn profile ?

Yes, Thomas Processing maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/thomas-processing.

How many cybersecurity incidents has Thomas Processing experienced ?

As of September 1, 2026, Rankiteo reports that Thomas Processing has not experienced any cybersecurity incidents.

How many peer or competitor companies does Thomas Processing have ?

Thomas Processing has an estimated 5,747 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Thomas Processing

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Thomas Processing Vendor Cyber Rating & Cyber Score

thomasprocessing.com

Add Your Compliance Badge

Founded in 1959, Thomas Processing is a global leader in the design, development, manufacturing and integration of pharmaceutical machinery, nutritional machinery, over-the-counter (OTC) tablet processing machinery and tablet press tooling. For more information about Thomas Processing LLC please visit www.thomaseng.com

Thomas Processing A.I CyberSecurity Scoring

Scoring History

Thomas Processing

Thomas Processing CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Thomas Processing Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Thomas Processing

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Thomas Processing in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Thomas Processing in 2026.

Incident Types Thomas Processing vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Thomas Processing in 2026.

Incident History - Thomas Processing (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Thomas Processing Subsidiaries

Thomas Processing

Pharmaceutical Manufacturing

Website: https://thomasprocessing.com/

Company Size: 0

IMA GroupAutomation Machinery Manufacturing

IMA AUTOMATIONAutomation Machinery Manufacturing

IMA AUTOMATION North AmericaMachinery Manufacturing

Ilapak Packaging MachineryMachinery Manufacturing

IMA PharmaFabbricazione di macchinari di automazione

TMC S.p.A. (Tissue Machinery Company)Machinery Manufacturing

Spares Service & MachineryMachinery Manufacturing

IMA Life North AmericaMachinery Manufacturing

Teknoweb ConvertingMachinery Manufacturing

IMA Iberica Processing and PackagingAutomation Machinery Manufacturing

Loading…

Thomas Processing Similar Companies

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Loading…

NEWS

Thomas Processing CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 14, 2025 07:00 AM

University of St. Thomas releases little information following massive data breach: Houston Chronicle

A hacking group has taken responsibility for a data breach at The University of St. Thomas, according to ABC13's partners at the Houston...

Read Article

August 26, 2025 07:00 AM

CPPA Adopts ADMT, Cybersecurity and Risk Assessment Regulations

The CPPA scratched another task off the to-do list last month when it officially adopted proposed regulations under CCPA.

Read Article

March 21, 2025 07:00 AM

Google Wants AI To Process Police Data Requests. It’s Not Going Well.

Google is hoping AI can deal with a glut of law enforcement requests for user data, but AI isn't yet up to the job.

Read Article

March 19, 2025 07:00 AM

Data chief raises concern about future of NHSE cyber security team

Guys' and St Thomas' NHS Foundation Trust's digital chief has called on the government not to scrap the NHS England cybersecurity team.

Read Article

March 08, 2025 08:00 AM

We call this kernel saunters: How Apple rearranged its XNU core with exclaves

Apple has been working to harden the XNU kernel that powers its various operating systems, including iOS and macOS, with a feature called exclaves.

Read Article

February 19, 2025 08:00 AM

Change Healthcare data breach: Industry 'not fine' 1 year later

It's been one year since the unprecedented Change Healthcare cyberattack crippled hospitals, medical groups, payers and pharmacies. For some providers,...

Read Article

December 20, 2024 08:00 AM

Ascension Ransomware Attack Affects 5.6 Million Patients

In May 2024, Ascension Health suffered a ransomware attack; however, it has taken months to determine how many individuals were affected.

Read Article

December 11, 2024 08:00 AM

The Double-Edged Sword of Generative AI

In Brief It is critical that accounting professionals understand the crucial role Generative Artificial Intelligence (Gen AI) plays in...

Read Article

August 29, 2024 07:00 AM

Accenture and Google Cloud Advance AI Adoption and Cybersecurity with Fortune 500 Companies

Accenture and Google Cloud today announced that their strategic alliance is advancing solutions for enterprise clients and seeing strong...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-83524

SUMMARY

A security vulnerability has been detected in RedPort Optimizer wXa-203, Optimizer wXa-213 and Optimizer wXa-223 up to 20260704. This impacts the function exec of the file /xgatev1/system/datetime.php of the component System Clock. The manipulation leads to command injection. The attack may be initiated remotely. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

CVE-2026-82971

SUMMARY

A vulnerability was determined in QVidium Opera11 3.3.2a26-Ax4x-opera11. This affects an unknown part of the file /cgi-bin/net_tr.cgi of the component CGI Script. This manipulation of the argument ipaddr causes command injection. The attack may be initiated remotely. The exploit has been publicly disclosed and may be utilized. The vendor explains: "QVidium has now closed its doors and no longer will be able to sell products or provide support." This vulnerability only affects products that are no longer supported by the maintainer.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 10)

cvss2

Base Score: 10.0

Complexity: LOW

AV:N/AC:L/Au:N/C:C/I:C/A:C

cvss3

Base Score: 10.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

CVE-2026-82957

SUMMARY

A vulnerability was found in hyperledger-firefly firefly up to 1.4.0. The impacted element is the function ValidateOptions of the file internal/events/webhooks/webhooks.go of the component Webhook Subscription. Performing a manipulation of the argument url results in server-side request forgery. Remote exploitation of the attack is possible. The exploit has been made public and could be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-82954

SUMMARY

A vulnerability was detected in Dokploy up to 0.29.7. This issue affects the function writeTraefikConfigInPath of the file packages/server/src/utils/traefik/application.ts of the component Settings. The manipulation of the argument path results in path traversal. The attack can be launched remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

CVE-2026-82922

SUMMARY

A security vulnerability has been detected in ShopEx ECShop up to 2.5.1. This vulnerability affects the function flow_update_cart of the file /flow.php?step=update_cart. The manipulation of the argument rec_id leads to sql injection. The attack can be initiated remotely. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-31

Updated

Date2026-08-31

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…